Climb Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-16.2%projected annual EPS growth
Analyst Coverage
14analysts covering
FY EPS (est.)
-$0.87next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Budoprutug B-cell depletion rate Quarterly9,000.0%Target: Average B-cell depletion of over 90% by Week 4
Budoprutug ITP mean platelet count increase Quarterly111KTarget: Sustained platelet count above 100,000 per microliter
Cash Runway Annually2KTarget: Fund operations into 2028
Watch Items
- Budoprutug Phase 2 PrisMN trial in primary membranous nephropathy (pMN) initial data readoutTrigger: Initial B-cell and anti-PLA2R data from low dose cohort in Q4 2026Action: Evaluate efficacy signals (complete/partial remission) and safety to inform Phase 3 dose selection.
- Budoprutug Phase 1b Systemic Lupus Erythematosus (SLE) global study initial data readoutTrigger: Initial B-cell data expected in Q4 2026Action: Assess safety, tolerability, and B-cell depletion depth to validate clinical activity in SLE.
- CLYM116 Phase 1 healthy volunteer study PK/PD data readoutTrigger: Initial PK/PD data expected in mid-2026Action: Review safety and translational modeling to support initiation of Phase 2 patient dosing in IgA nephropathy.
Research as of 20 Jun 2026